Connect with us

Mental health

New study reports reduced anxiety and depression from low-dose CBD

The findings address misconceptions that CBD needs to be consumed in high doses to be effective



CBD for anxiety and depression
The use of CBD products even at a low dose, was linked to reductions in both anxiety and depression.

A new study from the US has found that the use of CBD products, even at a low dose, was linked to reductions in both anxiety and depression.

The study led by non-profit organisation Realm of Caring (RoC), examined the benefits of medicinal cannabis products for individuals with anxiety and depression.

The data published in the medical journal Frontiers in Psychiatry, showed that individuals who initiated use of artisanal CBD products or continued use of CBD products at follow-up endorsed significant reductions in both anxiety and depression, improved sleep, and less pain compared with those not using CBD.

Researchers sourced data from an online web surveyRoC’s Observational Research Registry (ORR) – conducted over a four-year period (2016-2020) focusing on participants’ self-reported anxiety and depression symptoms, and the need for an assessment on non-pharmaceutical CBD products widely available to consumers. 

RoC was co-founded by Paige Figi, the mother of Charlotte Figi, whose story inspired the launch of global CBD brand Charlotte’s Web. The organisation is dedicated to cannabinoid research and improving access to cannabis-based therapies for those who could benefit.

Dr Nicolas Schlienz, research director for RoC, said the findings addressed misconceptions that CBD needs to be consumed in high doses to be effective for relieving symptoms. 

“The biggest misconception this study addresses is that CBD doses need to be between 400-600 mg before positive psychiatric effects can be achieved,” said Dr Schlienz.

“We observed positive effects in people taking an average of only about 60 mg per day, one tenth of that dose.”

 For information on joining RoC’s ongoing research

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.